The claim contains multiple inaccuracies when compared to the source abstract: (1) The threshold is wrong: claim states >1.0 mcg/mL (equivalent to >1.0 mg/L), but the abstract states >2.0 mg/L. (2) The odds ratio is wrong: claim states 5.70 (95% CI: 3.18-10.13), but the abstract states OR 10.17 (95% CI 1.10–94.38). The claimed OR of 5.7 with tight confidence interval (3.18-10.13) does not match the source's OR of 10.17 with very wide confidence interval (1.10-94.38). The wide CI in the source suggests high uncertainty, while the claimed CI suggests much more precision. (3) The units are slightly different in presentation (mcg/mL vs mg/L) though 1 mcg/mL = 1 mg/L, so this is technically equivalent but the threshold value itself is incorrect. The claim appears to be a substantial misrepresentation of the source findings.

Suggested fix: D-dimer >2.0 mg/L, OR 10.17 (95% CI: 1.10-94.38), P = 0.041. Note: The abstract also reports D-dimer >2.14 mg/L as optimal cutoff for predicting mortality with sensitivity 88.2% and specificity 71.3% (AUC 0.85; 95% CI = 0.77-0.92).

The claim states 'IL-6 >32 pg/mL' with 'Value: 22x' and 'OR 22.25 (95% CI: 8.52-58.10)'. The abstract contains NO such statistics. The abstract reports: (1) ratio of means = 2.9-fold higher IL-6 in complicated vs non-complicated COVID-19 (95% CI: 1.17-7.19), and (2) ratio of means = 3.24 for ICU vs non-ICU (95% CI: 2.54-4.14). The claim's '22x' value and 'OR 22.25' are completely absent. The abstract uses ratios of means, not odds ratios (OR). The specific threshold '>32 pg/mL' is not mentioned. The confidence intervals in the claim (8.52-58.10) do not match any values in the abstract. This appears to be a fabricated statistic that cannot be derived from any reasonable interpretation of the abstract data.

Suggested fix: IL-6 levels were 2.9-fold higher (95% CI: 1.17-7.19) in patients with complicated COVID-19 vs non-complicated disease, or 3.24-fold higher (95% CI: 2.54-4.14) in ICU vs non-ICU patients

The claim states OR 3.32 (95% CI: 2.48-4.45), but the abstract clearly reports OR=2.99 (95% CI: 1.31-6.82). The claimed point estimate (3.32 vs 2.99) and confidence interval (2.48-4.45 vs 1.31-6.82) both differ substantially from the source. The claimed value of '3.3x' appears to be a rounded version of 3.32, but this does not match the actual OR of 2.99 reported in the abstract. The confidence interval in the claim is much narrower and shifted higher than the actual CI in the source (1.31-6.82), which is a critical difference. The source uses a random effects model with wider uncertainty bounds. This appears to be either a misreading of a different statistic from the full paper, a different meta-analysis, or an error in transcription.

Suggested fix: Lymphopenia: OR 2.99 (95% CI: 1.31-6.82) for severe COVID-19

The claim presents mortality risk ratios by three D-dimer categories (<0.5, 1.0-2.0, >2.0 mcg/mL) with values 1.0, 5.7, and 11.15. However, the abstract only reports a single odds ratio for D-dimer >1 μg/mL of 18.42 (95% CI 2.64-128.55). The claimed values (1.0, 5.7, 11.15) do not match the source. The abstract does NOT show a graded analysis with three tiers, nor does it mention the specific cutoff values of 0.5 or 2.0 mcg/mL. The single reported OR of 18.42 for >1 μg/mL is substantially different from the claimed 11.15 for >2.0 mcg/mL. The claim appears to be either from a different analysis in the full paper (not the abstract), from a different paper entirely, or possibly fabricated/misremembered. The abstract only dichotomizes at 1 μg/mL, not the three-tier system claimed.

Suggested fix: D-dimer >1 μg/mL: OR 18.42 (95% CI 2.64-128.55) for in-hospital mortality. Note: Abstract does not report data for <0.5 mcg/mL or 1.0-2.0 mcg/mL categories.